Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/RAB11A_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/RAB11A_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/RAB11A_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RAB11A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RAB11A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RAB11A_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/RAB11A_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/RAB11A_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RAB11A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003150315 | Skin | cSCC | protein-containing complex localization | 95/4864 | 220/18723 | 2.00e-08 | 5.82e-07 | 95 |
GO:001619717 | Skin | cSCC | endosomal transport | 98/4864 | 230/18723 | 2.71e-08 | 7.41e-07 | 98 |
GO:190198714 | Skin | cSCC | regulation of cell cycle phase transition | 150/4864 | 390/18723 | 3.21e-08 | 8.61e-07 | 150 |
GO:190437524 | Skin | cSCC | regulation of protein localization to cell periphery | 59/4864 | 125/18723 | 2.52e-07 | 5.28e-06 | 59 |
GO:001604925 | Skin | cSCC | cell growth | 173/4864 | 482/18723 | 7.21e-07 | 1.34e-05 | 173 |
GO:000703215 | Skin | cSCC | endosome organization | 42/4864 | 82/18723 | 8.86e-07 | 1.63e-05 | 42 |
GO:004578717 | Skin | cSCC | positive regulation of cell cycle | 120/4864 | 313/18723 | 8.95e-07 | 1.64e-05 | 120 |
GO:005165018 | Skin | cSCC | establishment of vesicle localization | 70/4864 | 161/18723 | 1.02e-06 | 1.82e-05 | 70 |
GO:004593118 | Skin | cSCC | positive regulation of mitotic cell cycle | 56/4864 | 121/18723 | 1.11e-06 | 1.96e-05 | 56 |
GO:190307625 | Skin | cSCC | regulation of protein localization to plasma membrane | 49/4864 | 104/18723 | 2.71e-06 | 4.30e-05 | 49 |
GO:005164816 | Skin | cSCC | vesicle localization | 73/4864 | 177/18723 | 6.36e-06 | 8.92e-05 | 73 |
GO:009006815 | Skin | cSCC | positive regulation of cell cycle process | 92/4864 | 236/18723 | 7.33e-06 | 1.01e-04 | 92 |
GO:009887617 | Skin | cSCC | vesicle-mediated transport to the plasma membrane | 59/4864 | 136/18723 | 7.60e-06 | 1.04e-04 | 59 |
GO:190547524 | Skin | cSCC | regulation of protein localization to membrane | 72/4864 | 175/18723 | 8.12e-06 | 1.09e-04 | 72 |
GO:190199212 | Skin | cSCC | positive regulation of mitotic cell cycle phase transition | 43/4864 | 93/18723 | 1.94e-05 | 2.28e-04 | 43 |
GO:000008611 | Skin | cSCC | G2/M transition of mitotic cell cycle | 58/4864 | 137/18723 | 2.19e-05 | 2.54e-04 | 58 |
GO:004483911 | Skin | cSCC | cell cycle G2/M phase transition | 61/4864 | 148/18723 | 3.61e-05 | 3.90e-04 | 61 |
GO:199018214 | Skin | cSCC | exosomal secretion | 14/4864 | 20/18723 | 4.66e-05 | 4.85e-04 | 14 |
GO:006195122 | Skin | cSCC | establishment of protein localization to plasma membrane | 30/4864 | 60/18723 | 5.67e-05 | 5.67e-04 | 30 |
GO:190198913 | Skin | cSCC | positive regulation of cell cycle phase transition | 49/4864 | 115/18723 | 7.55e-05 | 7.24e-04 | 49 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RAB11A | SNV | Missense_Mutation | novel | c.189G>C | p.Gln63His | p.Q63H | P62491 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
RAB11A | SNV | Missense_Mutation | | c.31C>T | p.Leu11Phe | p.L11F | P62491 | protein_coding | deleterious_low_confidence(0.01) | benign(0.105) | TCGA-AQ-A0Y5-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD |
RAB11A | SNV | Missense_Mutation | rs759435629 | c.521N>A | p.Arg174His | p.R174H | P62491 | protein_coding | tolerated_low_confidence(0.31) | benign(0.001) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD |
RAB11A | SNV | Missense_Mutation | novel | c.158N>C | p.Ile53Thr | p.I53T | P62491 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.519) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
RAB11A | SNV | Missense_Mutation | novel | c.382N>G | p.Leu128Val | p.L128V | P62491 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.822) | TCGA-AG-3887-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | irinotecan | SD |
RAB11A | SNV | Missense_Mutation | novel | c.86C>A | p.Ser29Tyr | p.S29Y | P62491 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.711) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAB11A | SNV | Missense_Mutation | novel | c.461N>T | p.Ser154Leu | p.S154L | P62491 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.994) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RAB11A | SNV | Missense_Mutation | novel | c.221G>A | p.Arg74Gln | p.R74Q | P62491 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.827) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
RAB11A | SNV | Missense_Mutation | | c.386G>A | p.Arg129His | p.R129H | P62491 | protein_coding | deleterious_low_confidence(0.02) | benign(0.025) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
RAB11A | SNV | Missense_Mutation | novel | c.70N>C | p.Lys24Gln | p.K24Q | P62491 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |